Monthly Archives: May 2011

With Cephalon Buy, Teva Bets on Brand Drugs and More In-House Innovation

If commodity generics and in-licensing deals are all the rage, then Teva just strapped on a fanny pack with its $6.8 billion acquisition of Cephalon. The deal is expected to skyrocket Teva’s brand drug portfolio to $7 billion in annual sales, making Teva “not only the world’s largest generics company, but also one of the […]
Posted in Deals, Strategy | Tagged , , , , | 3 Comments

Did Digital Marketers Forget That Docs Write the Scripts?

Consumer drug marketing online is way smarter and more sophisticated than healthcare professional (HCP) efforts, with dollars continuing to favor sales forces over digital executions, according to L2’s Digital IQ index. Of the 70 brands assessed in the report, well over half were classified as “challenged” or “feeble” with respect to online and mobile prowess. […]
Posted in Advertising, E-Media, Marketing, social media, Strategy, Technology | Tagged , , | 1 Comment

Seeing Through the EU Transparency Directive

Reflector outlines why the EU’s so-called “transparency directive” has not set the industry on fire. For such a big subject, it is receiving little public attention. No matter how much pharma executives eulogise the heady prospects for personalised medicine or the protean potential of pharmacogenomics, everything all comes down, at the end of the day, […]
Posted in Europe, Global, Guest Blog, pricing, Regulatory | Tagged , , , | Leave a comment
  • Categories

  • Meta